Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2022

Genmab — December 2022

Planlagt Fastgjort Låst Flyttet Genmab
668 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #107

    E.L. I vote on you. 😉

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #108

      that wasn't exactly what i had in mind lol

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #109

        Julerally på aktiemarkedet? På de sociale aktiemedier og finansmedier bliver der lige nu gættet på livet løs om, hvorvidt vi kommer til at se et julerally i år. Hvad tror Helge Larsen? Og hvorfor? Derudover kommer han ind på Equinor, laksesektoren, Anavex og Genmab. https://www.proinvestor.com/boards/108513

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #110

          Hej Dublo, Jeg står op før kl. 5, men starter normalt først på Proinvestor kl. 6. Nyd din ferie, hvor end du er. 🙂

          1 Reply Last reply
          0
          • G Offline
            G Offline
            GeorgeBest
            wrote on sidst redigeret af
            #111

            ph I/II epcoritamab + R-DHAX transplant-eligible r/r DLBCL (n=29)

            • most common AEs hematologic, CRS (mild)
            • pts ➡️ ASCT ORR 100%
            • non-ASCT pts (mostly pt choice) ORR 64%
              fascinating data for the combination https://twitter.com/chanyooncheah/status/1600890760546914304?s=61&t=kTAfbfq899c3srDizGwYoA
            1 Reply Last reply
            0
            • D Offline
              D Offline
              Doublo
              wrote on sidst redigeret af
              #112

              God morgen fra Tyrkiet klart du må starte før kl. 5 Helge,
              eller kunne du slet ikke nå det du når.

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #113

                Godmorgen 🙂

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Stroka
                  wrote on sidst redigeret af
                  #114

                  God morgen 🙂

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    GeorgeBest
                    wrote on sidst redigeret af
                    #115

                    #ASH22 Talquetamab, a GPRC5D x CD3 Bispecific Antibody, in Patients with RRMM. At 0.4 mg/kg/week: ORR 73%, median PFS 7.5 months. https://twitter.com/transplant_doc/status/1600722580859949056?s=61&t=xzQrHseV4vIwvZlzzdG0vA

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #116

                      Genmab rider på en bølge af succes

                      David Mygind
                      Fredag 09. december https://ugebrev.dk/life-science/genmab-rider-paa-en-boelge-af-succes/

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #117

                        "Genmab: Præsenterede torsdag data for Gen1042 der var bedre end forventet" https://www.jyskebank.dk/finansnyt/morgennyt/2f4f3c0d-af87-4ffd-94d0-47e163666bb1 -I still can't find anything about it; we'll probably have to wait for the R&D day

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #118

                          Nsclc er en svær øvelse https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2022/12/08195320/Ipsen-Contact-Press-Release-12-2022-1.pdf

                          1 Reply Last reply
                          0
                          • nohopeN Offline
                            nohopeN Offline
                            nohope
                            wrote on sidst redigeret af
                            #119

                            The problem with Mygind is that according to him then is the sky over Genmab is not just always blue, it is luminiscent.

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              GeorgeBest
                              wrote on sidst redigeret af
                              #120

                              Well, the sky has been quite blue the last 10 years. Why would you make it grey then?

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #121

                                The sky above nohope is always black.

                                1 Reply Last reply
                                0
                                • StockBullS Offline
                                  StockBullS Offline
                                  StockBull
                                  wrote on sidst redigeret af
                                  #122

                                  Im ok with the moon

                                  1 Reply Last reply
                                  0
                                  • nohopeN Offline
                                    nohopeN Offline
                                    nohope
                                    wrote on sidst redigeret af
                                    #123

                                    You are probably right, we have to go back 10 years to make it look great.I can´t do 10 years, but this 5 years compared to Novo, which steadily pays annual dividend.https://imgur.com/a/DSOpp2a

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      GeorgeBest
                                      wrote on sidst redigeret af
                                      #124

                                      5 years looks okay for. Can I get the same return the next 5 years, I’ll be happy 🙂

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #125

                                        😄 Bulder

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #126

                                          Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-submits-biologics-license-application-to-us-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301699241.html

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper